XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial BERKELEY, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: ...

XOMA said the fixed-dose combination (FDC) of perindopril arginine combined with amlodipine besylate, licensed by the company from Les Laboratoires Servier, proved in a Phase III trial to be ...

In the ASCOT trial, perindopril added to amlodipine reduced more cardiovascular events than a thiazide added to atenolol, although this might be an effect of BP control.

A stepped regimen of amlodipine 5-10 mg/day with addition of perindopril 4 or 8 mg/day as required ('modern' regimen) was compared with a 'traditional' regimen of atenolol 50-100 mg/day with ...

With amlodipine overall, 3.9% of patients developed pedal edema, with no differences seen between the amlodipine/perindopril and amlodipine/HCTZ groups. “Pending trial evidence comparing the effects ...

In addition, Mr. Emerson and Dr. Feldstein managed the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hypertension), which demonstrated that the FDC of perindopril ...

We note that the perindopril franchise includes Aceon (perindopril erbumine), an angiotensin converting enzyme (ACE) inhibitor and three other fixed dose combination (:FDC) candidates. Aceon is ...

Emerson and Dr. Feldstein oversaw the 837-patient Phase III Perindopril Amlodipine for the Treatment of Hypertension (PATH) trial, which demonstrated that the FDC of perindopril arginine combined ...

Momentum Money Heroes Picture This: Huawei Photo Competition - Enter and win! Prevent & Protect with Sanofi Sustainable Impact with Standard Bank RU120 - Rhodes celebrates 120 years Government ...

CITY OF INDUSTRY, CA--(Marketwired - Jun 6, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for ...

To evaluate the persistence of the antihypertensive effect of perindopril 4 mg+indapamide 1.25 mg once daily for up to 72 h using the ‘missed-dose’ technique. Hypertensive patients were ...